Tissue distribution and excretion of intravenously administered titanium dioxide nanoparticles

Toxicology Letters

Volumn 205, Issue 1, 2011, Pages 55-61

  Xie, Guangping ^a   Wang, Chen ^a   Sun, Jiao ^a   Zhong, Gaoren ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Excretion; Labeling; Nanotoxicity; TiO2 NPs; Tissue distribution

Indexed keywords

IODINE 125; NANOPARTICLE; TITANIUM DIOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BRAIN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; EX VIVO STUDY; FECES ANALYSIS; FLUORESCENCE IMAGING; HEART; INTESTINE; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SPLEEN; TISSUE DISTRIBUTION; TRANSMISSION ELECTRON MICROSCOPY; URINARY EXCRETION; ZETA POTENTIAL;

ANIMALS; ELECTROCHEMISTRY; FECES; FLUORESCENT DYES; GAMMA RAYS; INJECTIONS, INTRAVENOUS; IODINE RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION; TITANIUM; WHOLE-BODY COUNTING;

MUS; RATTUS;

EID: 79959919111     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2011.04.034     Document Type: Article

References (21)

1. de la Garza L., Saponjic Z.V., Dimitrijevic N.M., Thurnauer M.C., Rajh T. Surface states of titanium dioxide nanoparticles modified with enediol ligands. J. Phys. Chem. B 2006, 110:680-686.
2. Esmaeili F., Ghahremani M.H., Esmaeili B., Khoshayand M.R., Atyabi F., Dinarvand R. PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int. J. Pharm. 2008, 349:249-255.
3. Fabian E., Landsiedel R., Ma-Hock L., Wiench K., Wohlleben W., van Ravenzwaay B. Tissue distribution and toxicity of intravenously administered titanium dioxide nanoparticles in rats. Arch. Toxicol. 2008, 82:151-157.
4. Fischer H.C., Chan W.C. Nanotoxicity: the growing need for in vivo study. Curr. Opin. Biotechnol. 2007, 18:565-571.
5. Geze A., Chau L.T., Choisnard L., Mathieu J.P., Marti-Batlle D., Riou L., Putaux J.L., Wouessidjewe D. Biodistribution of intravenously administered amphiphilic beta-cyclodextrin nanospheres. Int. J. Pharm. 2007, 344:135-142.
6. Hagens W.I., Oomen A.G., de Jong W.H., Cassee F.R., Sips A.J. What do we (need to) know about the kinetic properties of nanoparticles in the body?. Regul. Toxicol. Pharmacol. 2007, 49:217-229.
7. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5:496-504.
8. Liao C.M., Chiang Y.H., Chio C.P. Assessing the airborne titanium dioxide nanoparticle-related exposure hazard at workplace. J. Hazard. Mater. 2009, 162:57-65.
9. Lomer M.C., Hutchinson C., Volkert S., Greenfield S.M., Catterall A., Thompson R.P., Powell J.J. Dietary sources of inorganic microparticles and their intake in healthy subjects and patients with Crohn's disease. Br. J. Nutr. 2004, 92:947-955.
10. Maynard A.D., Aitken R.J., Butz T., Colvin V., Donaldson K., Oberdorster G., Philbert M.A., Ryan J., Seaton A., Stone V., Tinkle S.S., Tran L., Walker N.J., Warheit D.B. Safe handling of nanotechnology. Nature 2006, 444:267-269.
11. Oberdorster G., Oberdorster E., Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ. Health Perspect. 2005, 113:823-839.
12. Opanasopit P., Nishikawa M., Hashida M. Factors affecting drug and gene delivery: effects of interaction with blood components. Crit. Rev. Ther. Drug Carrier Syst. 2002, 19:191-233.
13. Saba T.M. Physiology and physiopathology of the reticuloendothelial system. Arch. Intern. Med. 1970, 126:1031-1052.
14. Sugibayashi K., Todo H., Kimura E. Safety evaluation of titanium dioxide nanoparticles by their absorption and elimination profiles. J. Toxicol. Sci. 2008, 33:293-298.
15. Takizawa Y., Nishimura H., Morota T., Tomisawa H., Takeda S., Aburada M. Pharmacokinetics of TJ-8117 (Onpi-to), a drug for renal failure (I): plasma concentration, distribution and excretion of [3H]-(-)epicatechin 3-O-gallate in rats and dogs. Eur. J. Drug Metab. Pharmacokinet. 2004, 29:91-101.
16. Tsuji J.S., Maynard A.D., Howard P.C., James J.T., Lam C.W., Warheit D.B., Santamaria A.B. Research strategies for safety evaluation of nanomaterials. Part IV. Risk assessment of nanoparticles. Toxicol. Sci. 2006, 89:42-50.
17. Wang J., Zhou G., Chen C., Yu H., Wang T., Ma Y., Jia G., Gao Y., Li B., Sun J., Li Y., Jiao F., Zhao Y., Chai Z. Acute toxicity and biodistribution of different sized titanium dioxide particles in mice after oral administration. Toxicol. Lett. 2007, 168:176-185.
18. Wang J.J., Sanderson B.J., Wang H. Cyto- and genotoxicity of ultrafine TiO2 particles in cultured human lymphoblastoid cells. Mutat. Res. 2007, 628:99-106.
19. Warheit D.B., Brock W.J., Lee K.P., Webb T.R., Reed K.L. Comparative pulmonary toxicity inhalation and instillation studies with different TiO2 particle formulations: impact of surface treatments on particle toxicity. Toxicol. Sci. 2005, 88:514-524.
20. Warheit D.B., Webb T.R., Reed K.L., Frerichs S., Sayes C.M. Pulmonary toxicity study in rats with three forms of ultrafine-TiO2 particles: differential responses related to surface properties. Toxicology 2007, 230:90-104.
21. Zhang J.S., Liu F., Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv. Drug. Deliv. Rev. 2005, 57:689-698.